<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671879</url>
  </required_header>
  <id_info>
    <org_study_id>MP511</org_study_id>
    <nct_id>NCT00671879</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back</brief_title>
  <official_title>Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of Carisoprodol Compared to Placebo in Subjects With Acute, Painful, Musculoskeletal Spasm of the Lower Back</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meda Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if two sustained released formulations of
      carisoprodol are more effective than placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:

      This will be a randomized, double-blind, double-dummy, placebo-controlled, parallel-group
      study in subjects 18-70 years of age with acute, painful, muscle spasm of the lower back. The
      study consists of a baseline screening (Study Day 1), during which subjects will be evaluated
      for inclusion/exclusion criteria, and a 7-day double-blind treatment period (Study Day 1
      through Study Day 7). Subjects will be randomly assigned to be dosed twice daily with one of
      the following double-blind treatments: SR carisoprodol 500-mg tablets, SR carisoprodol 700-mg
      tablets, or placebo.

      Subjects will be evaluated in the clinic on Study Days 1, 3 and 7. Subjects who remain
      symptomatic on Study Day 7 will be allowed to continue in the study for a 7-day, double-blind
      extension period at the discretion of the Investigator. Subjects will be contacted by
      telephone for a safety follow-up 7 days after the last dose of study medication.

      A pharmacokinetic (PK) substudy will be conducted at selected sites. These sites will obtain
      blood samples for PK analysis at the end of the 7-day treatment period and the 14-day
      treatment period, if applicable.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Rated Change Relief From Starting Backache of Pain on a 100-point Visual Analog Scale</measure>
    <time_frame>baseline to 14 days</time_frame>
    <description>on a visual analog scale of 0 to 100 millimeters(mm) with 0 being no pain and 100 being maximum pain By measuring the amount of pain before and during treatment done at each visit and recording the difference in mm.During treatment scores were averaged and this average was compared to the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Functional Assessment Based on the Roland-Morris Disability Questionnaire (RMDQ)</measure>
    <time_frame>baseline and day +14</time_frame>
    <description>Subject functional assessment based on the Roland-Morris Disability Questionnaire (RMDQ)at day 14.Subjects were asked to read a list of 24 sentences that people have used to describe themselves when they had back pain, and were asked to mark those statements that described their condition that day. The number of marked statements was added. A decrease in the number of marked statements from baseline represented improvement on the RMDQ.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">830</enrollment>
  <condition>Lower Back Pain</condition>
  <arm_group>
    <arm_group_label>Carisprodol SR 700 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carisoprodol 700 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carisoprodol SR 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carisoprodol SR 500 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carisoprodol SR 700 mg</intervention_name>
    <description>700 mg twice daily tablet</description>
    <arm_group_label>Carisprodol SR 700 mg</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carisoprodol SR 500 mg</intervention_name>
    <description>carisoprodol SR 500 mg tablet</description>
    <arm_group_label>Carisoprodol SR 500mg</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Onset of pain is within 3 days of first visit

          -  Subject rating of pain must be 40 mm or greater on VAS

          -  Ability to discontinue all analgesics, NSAIDs, and other muscle relaxants

          -  Willingness to provide written informed consent

          -  Must be in generally good health

        Exclusion Criteria:

          -  Presence of sciatic pain

          -  History of clinically significant spine pathology such as herniated nucleus pulpous,
             spondylolisthesis, spinal stenosis

          -  Presence of underlying chronic back pain

          -  Neurological signs and symptoms such as numbness, tingling, foot drop, paresthesia,
             unexplained constipation, urinary retention or urinary incontinence

          -  Myocardial infarction within one year of study

          -  Cancer not in remission or in remission less than one year

          -  HIV or other immunodeficiency syndromes

          -  History of osteoporosis or at high risk for vertebral fracture

          -  Underlying rheumatologic disease such as rheumatoid arthritis, ankylosing spondylitis,
             etc.

          -  Presence of active influenza or other viral syndromes

          -  Morbid obesity (BMI &gt;39)

          -  Evidence of infection, such as low grade fever or neutrophilia

          -  Existence of any medical/surgical condition that could interfere with the evaluation
             of the study medication

          -  Known history of alcohol or drug abuse

          -  Injury involving high potential for litigation, including worker's compensation or
             automobile accidents

          -  Pregnancy or breast feeding

          -  Women of child-bearing potential not abstinent or not practicing a medically
             acceptable method of contraception

          -  Vertebral body or spinous process, percussive tenderness on physical exam

          -  Any abnormalities in the following tests of both lower extremities: ankle dorsiflexion
             strength, great toe dorsiflexion strength, absent or hyperreflexic Achilles or
             patellar tendor reflexes, abnormal sensory exam in the medial, dorsal or lateral
             aspect of the foot and positive straight leg raise test

          -  Urgent medical conditions on comprehensive exam that might indicate a more serious
             condition should be treated urgently
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lewis M. Fredane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Meda Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brookwood Internists, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Shores General Practice Center</name>
      <address>
        <city>Gulf Shores</city>
        <state>Alabama</state>
        <zip>36547</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simon Williamson Clinic, PC</name>
      <address>
        <city>Hueytown</city>
        <state>Alabama</state>
        <zip>35023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaugh H Mancha Jr., PC Family Practice</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NextCare Institute for Clinical Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiel Family and Sports Medicine</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Ozarks</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality of life Medical, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICT - Beverly Hills</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chrishard Medical Group</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials and Powerplay</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newport Beach Clinical Research Associates, Inc.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Managed Care Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crest Clinical Trials, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Clinical Research Inc.</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinicos, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center, LLC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Institute of Clinical Research</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Network, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Assoc. of S. Broward, P.A.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FPA Clinical Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jay Care Medical Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West FL, Inc.</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslar Medical, Inc./ Osler Clinical Research</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homestead Clinical Research</name>
      <address>
        <city>Naranja</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andres Patron, DO, PA</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilker/Powers Center for Clinical Studies</name>
      <address>
        <city>St. Cloud</city>
        <state>Florida</state>
        <zip>34769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Rangel, M.D., P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Wind'r Research &amp; Development, LLC</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMI Health Research Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perimeter Institute for Clinical Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Clinical Research</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupage Family Medicine</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Orthopaedics &amp; Hand Care Research</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Clinic, APMC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterford Medical Associates</name>
      <address>
        <city>Waterford</city>
        <state>Michigan</state>
        <zip>48328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRC of Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Meera Dewan PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Association of International Professionals</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICT - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immedicenter</name>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <zip>07003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Land Clinical Studies</name>
      <address>
        <city>West Caldwell</city>
        <state>New Jersey</state>
        <zip>07006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odyssey Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parsons Avenue Medical Clinic</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harleysville Medical Associates</name>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <zip>19438</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warminster Medical Association</name>
      <address>
        <city>Warminster</city>
        <state>Pennsylvania</state>
        <zip>18974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeGarmo Institute of Medical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Family Medicine Center</name>
      <address>
        <city>Pelzer</city>
        <state>South Carolina</state>
        <zip>29669</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group, P.C.</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Clinic of North Texas</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DiscoveResearch, Inc.</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Family Care Clinical Research</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Medical Clinic</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>F. Adam Kawley, MD PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSA Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Health Research, LLC</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group, P.C.</name>
      <address>
        <city>Weber City</city>
        <state>Virginia</state>
        <zip>24290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <results_first_submitted>July 13, 2011</results_first_submitted>
  <results_first_submitted_qc>October 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2012</results_first_posted>
  <last_update_submitted>October 22, 2012</last_update_submitted>
  <last_update_submitted_qc>October 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carisoprodol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carisprodol SR 700 mg</title>
          <description>Carisoprodol 700 mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Carisoprodol SR 500mg</title>
          <description>Carisoprodol SR 500 mg twice daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo treatment arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="279"/>
                <participants group_id="P3" count="280"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="281"/>
                <participants group_id="P2" count="275"/>
                <participants group_id="P3" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carisprodol SR 700 mg</title>
          <description>Carisoprodol 700 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Carisoprodol SR 500mg</title>
          <description>Carisoprodol SR 500 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo treatment arm</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="281"/>
            <count group_id="B2" value="279"/>
            <count group_id="B3" value="280"/>
            <count group_id="B4" value="840"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="280"/>
                    <measurement group_id="B4" value="838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="12.35"/>
                    <measurement group_id="B2" value="41.6" spread="11.79"/>
                    <measurement group_id="B3" value="41.4" spread="11.86"/>
                    <measurement group_id="B4" value="41.5" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="280"/>
                    <measurement group_id="B4" value="840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Rated Change Relief From Starting Backache of Pain on a 100-point Visual Analog Scale</title>
        <description>on a visual analog scale of 0 to 100 millimeters(mm) with 0 being no pain and 100 being maximum pain By measuring the amount of pain before and during treatment done at each visit and recording the difference in mm.During treatment scores were averaged and this average was compared to the baseline value.</description>
        <time_frame>baseline to 14 days</time_frame>
        <population>intent to treat(ITT) population least square mean(LSMEAN, LSMEAN) diff vs Placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Carisprodol SR 700 mg</title>
            <description>Carisoprodol SR 700 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carisoprodol SR 500mg</title>
            <description>Carisoprodol SR 500 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Rated Change Relief From Starting Backache of Pain on a 100-point Visual Analog Scale</title>
          <description>on a visual analog scale of 0 to 100 millimeters(mm) with 0 being no pain and 100 being maximum pain By measuring the amount of pain before and during treatment done at each visit and recording the difference in mm.During treatment scores were averaged and this average was compared to the baseline value.</description>
          <population>intent to treat(ITT) population least square mean(LSMEAN, LSMEAN) diff vs Placebo</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="1.30"/>
                    <measurement group_id="O2" value="15.5" spread="1.34"/>
                    <measurement group_id="O3" value="15.2" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Functional Assessment Based on the Roland-Morris Disability Questionnaire (RMDQ)</title>
        <description>Subject functional assessment based on the Roland-Morris Disability Questionnaire (RMDQ)at day 14.Subjects were asked to read a list of 24 sentences that people have used to describe themselves when they had back pain, and were asked to mark those statements that described their condition that day. The number of marked statements was added. A decrease in the number of marked statements from baseline represented improvement on the RMDQ.</description>
        <time_frame>baseline and day +14</time_frame>
        <population>Intent to Treat(ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Carisprodol SR 700 mg</title>
            <description>Carisoprodol 700 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Carisoprodol SR 500mg</title>
            <description>Carisoprodol SR 500 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo treatment arm</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Functional Assessment Based on the Roland-Morris Disability Questionnaire (RMDQ)</title>
          <description>Subject functional assessment based on the Roland-Morris Disability Questionnaire (RMDQ)at day 14.Subjects were asked to read a list of 24 sentences that people have used to describe themselves when they had back pain, and were asked to mark those statements that described their condition that day. The number of marked statements was added. A decrease in the number of marked statements from baseline represented improvement on the RMDQ.</description>
          <population>Intent to Treat(ITT) population</population>
          <units>marked statements</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.64"/>
                    <measurement group_id="O2" value="5.0" spread="0.64"/>
                    <measurement group_id="O3" value="4.3" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Carisprodol SR 700 mg</title>
          <description>Carisoprodol 700 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Carisoprodol SR 500mg</title>
          <description>Carisoprodol SR 500 mg twice daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo treatment arm</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>atypical pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>severe influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="281"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.4</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="281"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>increased blood CPK</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="281"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="275"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="275"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="281"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>clumsiness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="281"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="281"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="275"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="281"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="275"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="281"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="275"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lasegues Test Positive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="281"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="281"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Ginsberg, DO Sr Dir Medical Scientific Affairs</name_or_title>
      <organization>Meda Pharma US</organization>
      <phone>732 564 2347</phone>
      <email>david.ginsberg@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

